Johnson & Johnson (NYSE:JNJ) Announces Quarterly Earnings Results

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Tuesday. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18, Zacks reports. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson updated its FY 2025 guidance to 10.500-10.700 EPS.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $154.08 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company’s fifty day moving average price is $159.38 and its 200 day moving average price is $155.11. The company has a market capitalization of $371.31 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a dividend of $1.30 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

An institutional investor recently raised its position in Johnson & Johnson stock. Brighton Jones LLC raised its position in Johnson & Johnson (NYSE:JNJ) by 13.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,876 shares of the company’s stock after buying an additional 6,332 shares during the period. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $7,502,000 as of its most recent SEC filing. 69.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Finally, Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Eight analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $171.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.